Industry Insight
Discovery Technology
Analytical Laboratory Technology
Delivery Systems
Ingredients, Formulation and Finishing
View our other publications with free access to extensive archives


 28th January 2011 Catalent Pharma Solutions

Catalent expert to present drug delivery solutions to enhance bioavailability of poorly soluble drugs at the controlled release society’s product development forum

SOMERSET, NJ, January 24, 2011 -- Jeffrey E. Browne, Ph.D. Technical Director, Pharmaceutical Softgel Business Development, Catalent Pharma Solutions, will be presenting at the Controlled Release Society’s (CRS) Product Development Forum for Poorly Soluble Drugs, January 27-29, 2011, in Miami, FL. Dr. Browne’s presentation, “Drug Delivery Technologies for Lipid-based Drug Delivery Systems – Current and Future Approaches” will take place on Friday, January 28, 2011 at 12:30 PM.

The presentation will focus on the use of lipid-based formulations for poorly water soluble drugs filled into softgels to enhance bioavailability. Dr. Browne will include a general review of bioavailability-enhancing technologies with an emphasis on the development of lipid-based delivery systems and the important role that dispersion and digestion play as formulation considerations. Additionally, the presentation will discuss the current utilization of softgel technology for the oral delivery of lipid-based systems as an immediate release dosage form. The presentation will conclude with a discussion of future uses of softgels including the encapsulation of lipid semi-solid/solid systems for modified release of drugs and the coating of softgels with functional film coating systems for targeting the release of lipid-based formulations in the gastrointestinal tract.

Throughout his career, Dr. Browne has held various positions in pharmaceutical manufacturing & technical services, as well as drug delivery R&D, with a focus on topical, transdermal, inhalation, and oral liquid dosage forms. In 1994, Dr. Browne joined Catalent Pharma Solutions (formerly RP Scherer and Cardinal Health Pharmaceutical Technologies & Services) and has expanded his expertise in a variety of positions and sites including: VP Softgel R&D in St. Petersburg, FL; Executive Director & Division Head of Pharmaceutical Development in Research Triangle Park, NC; Director of Technical Services in St. Petersburg, FL; Account Director, Business Development; and most recently, Technical Director, Pharmaceutical Softgels. Dr. Browne holds his Ph.D. in Industrial & Physical Pharmacy from Purdue University. He is active in the American Association of Pharmaceutical Scientists (AAPS), serving on several Focus Group committees and has presented frequently at regional and national AAPS meetings. He also serves on the Industrial Advisory Board of the Dane O. Kildsig Center for Pharmaceutical Processing Research, a center which encourages cooperative research between academia and industry.

To arrange a follow-up interview with Dr. Browne, please contact Patricia McGee at

For more information or to register for the conference, visit:

To learn more about Catalent’s softgel technologies, go to:

To contact Dr. Jeffrey Browne with specific softgel technology inquiries or to arrange a consultation with Dr. Browne and the softgel team at the upcoming Controlled Release Society’s (CRS) Product Development Forum for Poorly Soluble Drugs, please contact

About Catalent From drug and biologic development services to delivery technologies to supply solutions, Catalent Pharma Solutions has the deepest expertise, the broadest offerings and the most unique technologies in the industry. With over 75 years of experience, Catalent helps customers get more molecules to market faster, enhance product performance, and provide superior, reliable manufacturing and packaging solutions. Catalent employs approximately 9,000 people at 29 facilities worldwide and in fiscal year 2010 generated more than $1.7 billion in annual revenue. Catalent is headquartered in Somerset, NJ. For more information, visit

more products. better treatments. reliably supplied.™

Media contact: Patricia McGee T +1 (732) 537-6407


Advair,Flovent,VentolinSymbicort,Serevent,FlonaseAstelin Rhinocort
IPT © 2021 Innovations in Pharmaceutical Technology | Terms and Conditions | | UK Contacts |
Providing a platform of communication on new ideas, developments and innovations | UK Tel No. +44 20 77243456 | Back to top of page |